as of 11-03-2026 1:28pm EST
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
| Founded: | 2001 | Country: | Israel |
| Employees: | N/A | City: | HAIFA |
| Market Cap: | 12.5M | IPO Year: | 2026 |
| Target Price: | N/A | AVG Volume (30 days): | 57.2K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.44 | EPS Growth: | 31.46 |
| 52 Week Low/High: | $0.85 - $4.87 | Next Earning Date: | 11-16-2026 |
| Revenue: | $1,016,000 | Revenue Growth: | -23.95% |
| Revenue Growth (this year): | 902.46% | Revenue Growth (next year): | -100.00% |
| P/E Ratio: | -0.49 | Index: | N/A |
| Free Cash Flow: | -20221000.0 | FCF Growth: | N/A |
Director, 10% Owner
Avg Cost/Share
$1.50
Shares
833,334
Total Value
$1,250,001.00
Owned After
2,083,334
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Manieu Alexandre Weinstein | PLUR | Director, 10% Owner | Oct 23, 2026 | Buy | $1.50 | 833,334 | $1,250,001.00 | 2,083,334 |
See how PLUR stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "PLUR Pluri Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.